{"id":35204,"date":"2026-08-24T10:31:27","date_gmt":"2026-08-24T05:01:27","guid":{"rendered":"https:\/\/fundsindia.com\/blog\/?p=35204"},"modified":"2026-08-24T11:43:57","modified_gmt":"2026-08-24T06:13:57","slug":"alpha-viyash-scientific-ltd-equity-research-desk","status":"publish","type":"post","link":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204","title":{"rendered":"Alpha | Viyash Scientific Ltd. &#8211; Equity Research Desk"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png\"><img loading=\"lazy\" width=\"1024\" height=\"512\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1-1024x512.png\" alt=\"\" class=\"wp-image-35225\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1-1024x512.png 1024w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1-300x150.png 300w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1-768x384.png 768w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1-1536x768.png 1536w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Viyash Scientific Ltd. &#8211; One Integrated Platform, Two Healthcare Growth Engines<\/span><\/strong><\/h2>\n\n\n\n<p>Viyash Scientific Limited (formerly SeQuent Scientific Limited), headquartered in Hyderabad, is an integrated pharmaceutical platform operating across animal and human health, backed by in-house science and intellectual property. Viyash operates through two segments, Formulations and Active Pharmaceutical Ingredients (APIs), and runs a diversified portfolio of 90+ APIs, 140+ animal-health products and 30+ human-health products, sold to 250+ customers across 150+ countries. Its manufacturing footprint spans 16 facilities (including 10 API sites) across India, Spain, Turkey, Brazil and the USA, with backward integration for key APIs, supported by an R&amp;D base of 250+ scientists, 175+ patents filed and 1,000+ product registrations.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-36.png\"><img loading=\"lazy\" width=\"758\" height=\"506\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-36.png\" alt=\"\" class=\"wp-image-35207\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-36.png 758w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-36-300x200.png 300w\" sizes=\"(max-width: 758px) 100vw, 758px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Company Journey<\/span><\/strong><\/h2>\n\n\n\n<p>Viyash Scientific emerged from the merger of SeQuent Scientific and Viyash Life Sciences, bringing together two complementary businesses to create an integrated global pharmaceutical platform. SeQuent contributed its established Animal Health franchise, global customer base and regulatory capabilities, while Viyash added an IP-led Human Health business with strong R&amp;D, backward-integrated manufacturing and API capabilities. The merger, announced in September 2024 and made effective on December 16, 2025, is aimed at leveraging these complementary strengths through manufacturing, procurement, R&amp;D and cross-selling synergies. Renamed Viyash Scientific in January 2026, the combined entity is now positioned to pursue growth across both Animal and Human Health while strengthening its end-to-end capabilities.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41.jpeg\"><img loading=\"lazy\" width=\"1024\" height=\"571\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41-1024x571.jpeg\" alt=\"\" class=\"wp-image-35208\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41-1024x571.jpeg 1024w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41-300x167.jpeg 300w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41-768x428.jpeg 768w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41-1536x857.jpeg 1536w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/desktop.a5b48eba4748cc294a41-2048x1142.jpeg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Products and Services<\/span><\/strong><\/h2>\n\n\n\n<p>Viyash&#8217;s product portfolio spans APIs, finished formulations and CDMO services across Human and Animal Health. Its Human Health portfolio includes 75+ commercial APIs across therapeutic categories such as CNS, cardiovascular, GI, anti-bacterial and oncology, alongside 50 marketed finished-dosage products. In Animal Health, the company offers 30+ commercial veterinary APIs, with a strong presence in anti-helminthic and anti-parasitic products, as well as 1,000+ finished formulations catering to livestock, poultry and companion animals. Its CDMO platform provides custom synthesis, API and formulation development, scale-up and commercial manufacturing, with specialised capabilities in high-potency and cytotoxic products.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37.png\"><img loading=\"lazy\" width=\"1024\" height=\"684\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37-1024x684.png\" alt=\"\" class=\"wp-image-35209\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37-1024x684.png 1024w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37-300x201.png 300w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37-768x513.png 768w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37-1536x1027.png 1536w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-37.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Subsidiaries<\/strong>: As of FY26, the company has 19 subsidiaries and no joint ventures\/associate companies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-38.png\"><img loading=\"lazy\" width=\"823\" height=\"306\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-38.png\" alt=\"\" class=\"wp-image-35210\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-38.png 823w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-38-300x112.png 300w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-38-768x286.png 768w\" sizes=\"(max-width: 823px) 100vw, 823px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Investment Rationale<\/span><\/strong><\/h2>\n\n\n\n<ul><li><strong>Companion Animal Health provides a long runway for portfolio expansion<\/strong> &#8211; Viyash is strengthening its presence in the growing companion animal market, where it currently has 10+ commercial products against a pipeline of 66+ products under development. The pipeline spans key therapeutic areas including parasiticides, dermatology, pain management, cardiology and anti-infectives, providing multiple avenues for portfolio expansion. The proposed acquisition of Italy-based BioForLife would add 85\u201390 companion-animal products and access to ~85% of veterinary clinics in Italy. The company has also entered India&#8217;s companion animal market through its strategic partnership with Boehringer Ingelheim India, providing access to a rapidly formalising market. Management aims to build $150\u2013200mn of Companion Animal revenue by 2032, supporting its ambition to become a Top-10 global Animal Health player.<\/li><\/ul>\n\n\n\n<ul><li><strong>Integrated platform creates multiple avenues for product and customer expansion<\/strong> &#8211; The merger has brought together complementary capabilities across Animal Health, Human Health, APIs, formulations and R&amp;D, creating opportunities for cross-selling, procurement synergies and better utilisation of the combined manufacturing network. Viyash&#8217;s &gt;85% backward integration provides greater control over key intermediates and APIs, while the company is increasingly internalising complex products and shifting select manufacturing to India to improve cost competitiveness. Capacity expansion in Spain and debottlenecking in Turkey, alongside the development of complex and high-potency products, should further enhance manufacturing flexibility and product capabilities. The sizeable pipeline of 24 Animal Health APIs and 63 Human Health APIs, including first-to-file opportunities, provides additional scope to broaden the portfolio.<\/li><\/ul>\n\n\n\n<ul><li><strong>Q1FY27<\/strong> &#8211; During Q1 FY27, the company reported consolidated revenue from operations of \u20b9946 crore, up 19.5% YoY (and 2.9% QoQ), with gross margin expanding ~220 bps YoY to 54.1%. ESOP-adjusted EBITDA rose 59.2% YoY to \u20b9205 crore, with EBITDA margin expanding ~530 bps YoY to 21.6%, driven by a richer product mix, operating leverage and post-merger integration synergies. Profit before tax more than doubled to \u20b9112 crore (up 132.8% YoY) and profit after tax grew 114.9% YoY to \u20b979 crore, supported by lower finance costs on reduced debt. The company closed the quarter with net debt of \u20b986 crore and net debt to LTM EBITDA of 0.1x, versus 0.2x in Q4FY26.<\/li><\/ul>\n\n\n\n<ul><li><strong>FY26<\/strong> &#8211; During FY26, the company reported consolidated revenue of \u20b93,420 crore, a 13.8% YoY increase over \u20b93,007 crore in FY25, with gross margin of 54.3% (versus 51.1%). ESOP-adjusted EBITDA rose 59.6% YoY to \u20b9703 crore at a 20.5% margin (versus 14.6%), while profit after tax increased to \u20b9225 crore from \u20b916 crore in FY25 as finance costs fell on lower debt and operating leverage improved.<\/li><\/ul>\n\n\n\n<ul><li><strong>Financial Performance<\/strong> &#8211; The three-year revenue CAGR stands at 34%, while net profit turned around from a loss of \u20b9122 crore in FY23 to a profit of \u20b9225 crore in FY26; both metrics are materially amplified by the FY26 amalgamation of Viyash Life Sciences into the erstwhile SeQuent Scientific, whose standalone animal-health business had grown at only a mid-single-digit revenue CAGR pre-merger. The three-year average ROE and ROCE are ~4% and ~7%, improving to 7% and 13% in FY26 as the integrated platform scaled and margins recovered. The company has sharply deleveraged, cutting net debt to EBITDA from 1.4x in Q1 FY25 to 0.1x in Q1 FY27, and generated operating cash flow of \u20b9323 crore in FY26 (~59% of operating profit).<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-39.png\"><img loading=\"lazy\" width=\"756\" height=\"354\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-39.png\" alt=\"\" class=\"wp-image-35211\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-39.png 756w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-39-300x140.png 300w\" sizes=\"(max-width: 756px) 100vw, 756px\" \/><\/a><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-40.png\"><img loading=\"lazy\" width=\"757\" height=\"215\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-40.png\" alt=\"\" class=\"wp-image-35212\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-40.png 757w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-40-300x85.png 300w\" sizes=\"(max-width: 757px) 100vw, 757px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Industry<\/span><\/strong><\/h2>\n\n\n\n<p>The Indian healthcare sector grew at a 17.5-22.5% CAGR, from US$ 372 billion in 2023 to US$ 638 billion in 2025, with healthcare spending expected to rise from 3.34% of GDP in 2023 towards ~5% by 2030 and a Ministry of Health &amp; Family Welfare allocation of \u20b91,06,530 crore in Union Budget FY27, a ~10% increase over the prior year. Within this, pharmaceuticals remain a structural export engine: India&#8217;s pharmaceutical exports are projected to scale to US$ 350 billion by FY47 from US$ 30.38 billion in FY25, aided by trade agreements such as the India-UK FTA of July 2025, which secures zero tariffs on ~99% of exports. The Drugs &amp; Pharmaceuticals sector has attracted cumulative FDI of US$ 24.85 billion between January 2000 and December 2025, reflecting India&#8217;s positioning as a global pharmaceutical and R&amp;D hub underpinned by cost advantages, backward-integrated manufacturing and a stable regulatory environment. GST 2.0 has further rationalised indirect taxes across the value chain, applying a uniform 5% rate to most medicines and lowering device and consumable levies, supporting affordability and volume growth for domestic manufacturers of APIs and formulations across both human and animal health.<\/p>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Growth Drivers<\/span><\/strong><\/h2>\n\n\n\n<ul><li><strong>Export-led Pharmaceutical Tailwinds<\/strong>: India&#8217;s pharmaceutical exports are projected to grow 10 to 15 times to US$ 350 billion by FY47 from US$ 30.38 billion in FY25, with the India-UK FTA of July 2025 enabling zero tariffs on ~99% of exports, expanding the addressable opportunity for export-oriented API and formulation platforms.<\/li><li><strong>Favourable FDI and Policy Environment:<\/strong> 100% FDI is permitted under the automatic route for greenfield projects, with the Drugs &amp; Pharmaceuticals sector attracting cumulative inflows of US$ 24.85 billion between January 2000 and December 2025, reinforcing India&#8217;s status as a global pharmaceutical and R&amp;D hub built on cost competitiveness and a stable regulatory framework.<\/li><li><strong>Structural Demand across Human and Animal Health:<\/strong> Rising income levels, an ageing population (life expectancy projected to reach 84 years by 2045) and a shift towards lifestyle diseases are lifting demand for both routine and specialised therapies, with the broader healthcare sector compounding at 17.5-22.5% towards US$ 638 billion by 2025 and healthcare spend rising towards ~5% of GDP by 2030.<\/li><\/ul>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Peer Analysis<\/span><\/strong><\/h2>\n\n\n\n<p>The company&#8217;s peer set includes Granules India Ltd, Aarti Drugs Ltd, etc.<\/p>\n\n\n\n<p>Compared with its peers, Viyash screens as the fastest-growing on reported revenue and among the most improved on profitability, aided by a sharply deleveraged balance sheet; however, its three-year sales CAGR is materially amplified by the FY26 amalgamation, and its return ratios still trail the established API and formulation peers as post-merger integration matures. This turnaround momentum and its differentiated integrated animal-and-human-health positioning are reflected in a premium earnings multiple relative to the peer set.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-41.png\"><img loading=\"lazy\" width=\"1024\" height=\"159\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-41-1024x159.png\" alt=\"\" class=\"wp-image-35213\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-41-1024x159.png 1024w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-41-300x47.png 300w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-41-768x119.png 768w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-41.png 1397w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Outlook<\/span><\/strong><\/h2>\n\n\n\n<p>Viyash&#8217;s outlook is supported by the benefits of the merger, ongoing cost optimisation and greater backward\/vertical integration, which should strengthen its competitive positioning. FY27 priorities remain focused on expanding the Companion Animal portfolio, scaling oncology formulations and developing differentiated APIs, with R&amp;D continuing to be the core growth driver. Animal Health is expected to remain the key growth engine, supported by increasing genericisation, geographic expansion and new product launches. At the same time, greater manufacturing integration and product diversification should support portfolio quality and strengthen the company&#8217;s overall financial profile.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-42.png\"><img loading=\"lazy\" width=\"1024\" height=\"712\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-42-1024x712.png\" alt=\"\" class=\"wp-image-35214\" srcset=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-42-1024x712.png 1024w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-42-300x208.png 300w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-42-768x534.png 768w, https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/image-42.png 1226w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Valuations<\/span><\/strong><\/h2>\n\n\n\n<p>We believe Viyash is well positioned to capitalise on the structural growth in global Animal Health, supported by its integrated and backward-linked platform, strong regulatory capabilities, expanding R&amp;D pipeline and multiple long-term growth opportunities across Companion Animal Health, differentiated APIs and strategic M&amp;A. We recommend a BUY rating in the stock with the target price (TP) of \u20b9333, 49x FY28E EPS. We also encourage maintaining a stop-loss at 20% from the entry price to manage potential downside risk effectively.<\/p>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">SWOT Analysis<\/span><\/strong><\/h2>\n\n\n\n<table style=\"width:100%; border-collapse:collapse; font-family:Arial, sans-serif; font-size:14px;\">\n  <tr>\n    <td style=\"width:50%; background-color:#1a7a4a; color:#ffffff; font-weight:bold; padding:10px 12px; text-align:center; border:1px solid #ccc;\">Strength<\/td>\n    <td style=\"width:50%; background-color:#e67e22; color:#ffffff; font-weight:bold; padding:10px 12px; text-align:center; border:1px solid #ccc;\">Weakness<\/td>\n  <\/tr>\n  <tr>\n    <td style=\"padding:12px; vertical-align:top; border:1px solid #ccc; background-color:#eafaf1;\">\n      <ul style=\"margin:0; padding-left:16px; line-height:1.7;\">\n        <li>Diversified platform across Animal Health, Human Health, APIs and formulations.<\/li>\n        <li>Strong backward integration across APIs and key intermediates.<\/li>\n        <li>Established global Animal Health franchise with strong regulatory capabilities.<\/li>\n      <\/ul>\n    <\/td>\n    <td style=\"padding:12px; vertical-align:top; border:1px solid #ccc; background-color:#fef5e7;\">\n      <ul style=\"margin:0; padding-left:16px; line-height:1.7;\">\n        <li>High exposure to regulated international markets.<\/li>\n        <li>Forex risk due to significant international operations.<\/li>\n      <\/ul>\n    <\/td>\n  <\/tr>\n  <tr>\n    <td style=\"background-color:#2471a3; color:#ffffff; font-weight:bold; padding:10px 12px; text-align:center; border:1px solid #ccc;\">Opportunities<\/td>\n    <td style=\"background-color:#c0392b; color:#ffffff; font-weight:bold; padding:10px 12px; text-align:center; border:1px solid #ccc;\">Threats<\/td>\n  <\/tr>\n  <tr>\n    <td style=\"padding:12px; vertical-align:top; border:1px solid #ccc; background-color:#eaf4fb;\">\n      <ul style=\"margin:0; padding-left:16px; line-height:1.7;\">\n        <li>Companion Animal Health offers a large runway for new product launches and geographic expansion.<\/li>\n        <li>Large R&#038;D pipeline across differentiated APIs, oncology and Companion Animal products.<\/li>\n        <li>Merger synergies, vertical integration and strategic M&#038;A offer scope to strengthen capabilities and expand the portfolio.<\/li>\n      <\/ul>\n    <\/td>\n    <td style=\"padding:12px; vertical-align:top; border:1px solid #ccc; background-color:#fdedec;\">\n      <ul style=\"margin:0; padding-left:16px; line-height:1.7;\">\n        <li>Increasing competition and price pressure across Animal Health generics.<\/li>\n        <li>Delays or failures in regulatory approvals could impact product launches and growth.<\/li>\n      <\/ul>\n    <\/td>\n  <\/tr>\n<\/table>\n\n\n\n\n<p><a href=\"https:\/\/www.fundsindia.com\/user\/equity?utm_source=clicks&amp;utm_medium=Blog&amp;utm_campaign=Alpha_Blog_Clicks&amp;utm_term=Blog_CTA\"><img loading=\"lazy\" src=\"https:\/\/lh7-rt.googleusercontent.com\/docsz\/AD_4nXceS__GzRS05ubM2opGwf3LkP5BWGjd0wY0nxrnt_yWACJbd9vZEZc0CSi02xWxObbTrv9Xj4_J0fNjfyYBjCMDsCUCQ1VkTZNr6yPlKsknTTO0RAiMxDRumhCaY8KArzlK1m_VJYk1N6Pa1mSpegI?key=HdXWVtHJW8EEqiLEr-EHwsuq\" width=\"300\" height=\"43\"><\/a><\/p>\n\n\n\n<p><strong>Disclaimer<\/strong>: Investments in the securities market are subject to market risks, read all related documents carefully before investing. Securities quoted here are exemplary, not recommendatory. Please consult your financial advisor before investing. Please note that we do not guarantee any assured returns for the securities quoted here.<\/p>\n\n\n\n<p>Research disclaimer: Investment in the securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n\n\n\n<p>For more details, please read the <a href=\"https:\/\/fundsindia-marketing-assets.s3.ap-south-1.amazonaws.com\/Disclaimer-final.pdf\">disclaimer.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viyash Scientific Ltd. &#8211; One Integrated Platform, Two Healthcare Growth Engines Viyash Scientific Limited (formerly SeQuent Scientific Limited), headquartered in Hyderabad, is an integrated pharmaceutical platform operating across animal and human health, backed by in-house science and intellectual property. Viyash operates through two segments, Formulations and Active Pharmaceutical Ingredients (APIs), and runs a diversified portfolio [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35225,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[743,59],"tags":[745,1063,1120,903,1046,1257,614,1370,1246],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v17.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Viyash Scientific Ltd.: Building Two Healthcare Growth Engines<\/title>\n<meta name=\"description\" content=\"Integrated Animal Health, Human Health &amp; API Capabilities Driving Long-Term Growth\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viyash Scientific Ltd.: Building Two Healthcare Growth Engines\" \/>\n<meta property=\"og:description\" content=\"Integrated Animal Health, Human Health &amp; API Capabilities Driving Long-Term Growth\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204\" \/>\n<meta property=\"og:site_name\" content=\"Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fundsindia\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T05:01:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T06:13:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Equities Desk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\",\"name\":\"Wealth India Financial Services\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/fundsindia\"],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"contentUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"width\":189,\"height\":200,\"caption\":\"Wealth India Financial Services\"},\"image\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"name\":\"Insights\",\"description\":\"Official blog of FundsIndia.com\",\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png\",\"contentUrl\":\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png\",\"width\":2048,\"height\":1024},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#webpage\",\"url\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204\",\"name\":\"Viyash Scientific Ltd.: Building Two Healthcare Growth Engines\",\"isPartOf\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#primaryimage\"},\"datePublished\":\"2026-08-24T05:01:27+00:00\",\"dateModified\":\"2026-08-24T06:13:57+00:00\",\"description\":\"Integrated Animal Health, Human Health & API Capabilities Driving Long-Term Growth\",\"breadcrumb\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fundsindia.com\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha | Viyash Scientific Ltd. &#8211; Equity Research Desk\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#article\",\"isPartOf\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#webpage\"},\"author\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\"},\"headline\":\"Alpha | Viyash Scientific Ltd. &#8211; Equity Research Desk\",\"datePublished\":\"2026-08-24T05:01:27+00:00\",\"dateModified\":\"2026-08-24T06:13:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#webpage\"},\"wordCount\":1633,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png\",\"keywords\":[\"FundsIndia Equity Research\",\"FundsIndia insights\",\"healthcare stock\",\"Long term investing\",\"pharma stock\",\"portfoliomanagement\",\"stock market\",\"viyash scientific\",\"wealth management\"],\"articleSection\":[\"Alpha\",\"Equity Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#respond\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\",\"name\":\"Equities Desk\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"caption\":\"Equities Desk\"},\"sameAs\":[\"http:\/\/www.fundsindia.com\"],\"url\":\"https:\/\/fundsindia.com\/blog\/author\/equities-desk\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viyash Scientific Ltd.: Building Two Healthcare Growth Engines","description":"Integrated Animal Health, Human Health & API Capabilities Driving Long-Term Growth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204","og_locale":"en_US","og_type":"article","og_title":"Viyash Scientific Ltd.: Building Two Healthcare Growth Engines","og_description":"Integrated Animal Health, Human Health & API Capabilities Driving Long-Term Growth","og_url":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204","og_site_name":"Insights","article_publisher":"https:\/\/www.facebook.com\/fundsindia","article_published_time":"2026-08-24T05:01:27+00:00","article_modified_time":"2026-08-24T06:13:57+00:00","og_image":[{"width":2048,"height":1024,"url":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png","type":"image\/png"}],"twitter_misc":{"Written by":"Equities Desk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.fundsindia.com\/blog\/#organization","name":"Wealth India Financial Services","url":"https:\/\/www.fundsindia.com\/blog\/","sameAs":["https:\/\/www.facebook.com\/fundsindia"],"logo":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#logo","inLanguage":"en-US","url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","contentUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","width":189,"height":200,"caption":"Wealth India Financial Services"},"image":{"@id":"https:\/\/www.fundsindia.com\/blog\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.fundsindia.com\/blog\/#website","url":"https:\/\/www.fundsindia.com\/blog\/","name":"Insights","description":"Official blog of FundsIndia.com","publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#primaryimage","inLanguage":"en-US","url":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png","contentUrl":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png","width":2048,"height":1024},{"@type":"WebPage","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#webpage","url":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204","name":"Viyash Scientific Ltd.: Building Two Healthcare Growth Engines","isPartOf":{"@id":"https:\/\/www.fundsindia.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#primaryimage"},"datePublished":"2026-08-24T05:01:27+00:00","dateModified":"2026-08-24T06:13:57+00:00","description":"Integrated Animal Health, Human Health & API Capabilities Driving Long-Term Growth","breadcrumb":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fundsindia.com\/blog"},{"@type":"ListItem","position":2,"name":"Alpha | Viyash Scientific Ltd. &#8211; Equity Research Desk"}]},{"@type":"Article","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#article","isPartOf":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#webpage"},"author":{"@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656"},"headline":"Alpha | Viyash Scientific Ltd. &#8211; Equity Research Desk","datePublished":"2026-08-24T05:01:27+00:00","dateModified":"2026-08-24T06:13:57+00:00","mainEntityOfPage":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#webpage"},"wordCount":1633,"commentCount":0,"publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"image":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#primaryimage"},"thumbnailUrl":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png","keywords":["FundsIndia Equity Research","FundsIndia insights","healthcare stock","Long term investing","pharma stock","portfoliomanagement","stock market","viyash scientific","wealth management"],"articleSection":["Alpha","Equity Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fundsindia.com\/blog\/equities\/alpha-viyash-scientific-ltd-equity-research-desk\/35204#respond"]}]},{"@type":"Person","@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656","name":"Equities Desk","image":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#personlogo","inLanguage":"en-US","url":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","caption":"Equities Desk"},"sameAs":["http:\/\/www.fundsindia.com"],"url":"https:\/\/fundsindia.com\/blog\/author\/equities-desk"}]}},"jetpack_featured_media_url":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/08\/Vijaya-Diagnostic-Centre-Ltd-1.png","_links":{"self":[{"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/35204"}],"collection":[{"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/comments?post=35204"}],"version-history":[{"count":7,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/35204\/revisions"}],"predecessor-version":[{"id":35226,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/35204\/revisions\/35226"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/media\/35225"}],"wp:attachment":[{"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/media?parent=35204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/categories?post=35204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fundsindia.com\/blog\/wp-json\/wp\/v2\/tags?post=35204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}